XORTX Therapeutics (XRTX) Net Income towards Common Stockholders (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Net Income towards Common Stockholders came in at -$823297.0 in Q1 2026, up 14.55% YoY from -$718738.4 in Q1 2025, and up 84.25% on a QoQ basis from -$5.2 million in Q4 2025.
XORTX Therapeutics (XRTX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$823297.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 14.55% year-over-year to -$823297.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 140.12% YoY) and the FY2025 annual result came in at $1.9 million, down 21.44% from the prior year.
- Net Income towards Common Stockholders grew to -$823297.0 in Q1 2026, from -$5.2 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $143709.0 in Q4 2024 to a low of -$5.2 million in Q4 2025.
- A 5-year average of -$1.4 million and a median of -$1.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 52.86% — and 2025, when it plunged 3736.45%.
- Tracing XRTX's Net Income towards Common Stockholders over 5 years: stood at -$1.6 million in 2022, then rose by 12.02% to -$1.4 million in 2023, then surged by 110.31% to $143709.0 in 2024, then sank by 3736.45% to -$5.2 million in 2025, then surged by 84.25% to -$823297.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$823297.0 (Q1 2026), -$5.2 million (Q4 2025), and -$716197.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | -823,297.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -823,297.00 |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -716,197.00 |
| Jun 30, 2025 | -889,945.00 |
| Mar 31, 2025 | -963,456.00 |
| Dec 31, 2024 | 143,709.00 |
| Sep 30, 2024 | -874,749.00 |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -1.09 Mn |
| Sep 30, 2023 | -1.39 Mn |
| Jun 30, 2023 | -1.26 Mn |
| Mar 31, 2023 | -1.36 Mn |
| Dec 31, 2022 | -1.58 Mn |
| Sep 30, 2022 | -917,922.54 |
| Jun 30, 2022 | -971,672.58 |
| Mar 31, 2022 | -2.87 Mn |
| Dec 31, 2021 | 308,203.93 |
| Sep 30, 2021 | -321,636.47 |
| Jun 30, 2021 | -704,063.01 |
| Mar 31, 2021 | -608,734.24 |